Skip to main content
. Author manuscript; available in PMC: 2014 Apr 17.
Published in final edited form as: Clin Cancer Res. 2007 Jun 1;13(11):3388–3394. doi: 10.1158/1078-0432.CCR-06-0873

Fig. 4.

Fig. 4

Imexon treatment results in increased nuclear protein expression of Nrf2. A, Western blot of nuclear extracts prepared from RPMI8226 myeloma cells treated with 0, 100, 300, and 500 μmol/L imexon for 1, 4, and 16 h and probed with antibodies for Nrf1 and Nrf2. Lamin A/C was used as loading control. B, Western blot of cytoplasmic extracts prepared as described above. Actin was used as a loading control. NS, nonspecific band. C, Western blot of nuclear and cytoplasmic extracts prepared from MDA-mb-231 breast cancer cells treated with 0, 100, 300, and 500 μmol/L imexon for 16 h and probed with antibodies for Nrf2 and lamin A/C or actin as loading controls.